Published in Breast Cancer Res Treat on January 01, 1983
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Breast cancer (1) N Engl J Med (1992) 4.79
Analysis of amino acid phenylthiohydantoins by gas chromatography. J Biol Chem (1969) 4.50
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol (1992) 3.15
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep (1985) 2.97
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Advances in the gas chromatographic analysis of amino acid phenyl- and methylthiohydantoins. Anal Biochem (1972) 2.56
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev (1987) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Mechanism of action of glucocorticoids. Metabolism (1974) 2.04
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res (1978) 1.97
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute. J Clin Oncol (1992) 1.89
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation. Breast Cancer Res Treat (1983) 1.80
Effects of inhibition of basement membrane collagen deposition on rat mammary gland development. Dev Biol (1980) 1.79
The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun (1978) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol (1987) 1.72
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Differential response to growth factor by rat mammary epithelium plated on different collagen substrata in serum-free medium. Proc Natl Acad Sci U S A (1981) 1.69
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol (1989) 1.65
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A (1987) 1.61
Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. J Natl Cancer Inst (1996) 1.60
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol (1988) 1.59
Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res (1986) 1.58
The relationship of hormone-sensitive and hormone-insensitive phosphatidylinositol to phosphatidylinositol 4,5-bisphosphate in the WRK-1 cell. J Biol Chem (1986) 1.58
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res (1990) 1.57
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Oestrogen-responsive human breast cancer in long term tissue culture. Nature (1975) 1.56
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat (1987) 1.54
The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med (1978) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res (1987) 1.54
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
Multiple estrogen receptor assays in human breast cancer. Cancer Res (1983) 1.52
Basement membrane collagen requirements for attachment and growth of mammary epithelium. Exp Cell Res (1979) 1.52
Structural changes in memebranes of synchronized cells demonstrated by freeze-cleavage. Nature (1971) 1.51
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Effects of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Res (1979) 1.44
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science (1986) 1.41
Breast cancer (2). N Engl J Med (1992) 1.39
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res (1983) 1.37
Growth factors in breast cancer. Endocr Rev (1995) 1.37
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res (1991) 1.36
Oestrogen receptors and breast cancer. BMJ (1997) 1.35
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res (1979) 1.35
Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer (1980) 1.34
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res (2001) 1.34
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res (1993) 1.32
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res (1993) 1.32
Human apolipoprotein A-I and A-II metabolism. J Lipid Res (1982) 1.32
Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res (1988) 1.32
Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol Endocrinol (1988) 1.31
Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. J Biol Chem (1984) 1.31
Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst (1993) 1.30
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res (1980) 1.29